FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2534379449> ?p ?o ?g. }

• W2534379449 endingPage "408" @default.
• W2534379449 startingPage "408" @default.
• W2534379449 abstract "Abstract Abstract 408 Introduction: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) is the current standard of care for the treatment of diffuse large B cell lymphoma (DLBCL). Doxorubicin has an integral role but is associated with significant toxicity. The omission of doxorubicin in patients who are frail, have poor baseline cardiac function or who have previously received anthracycline therapy may compromise outcome. However, the recent introduction of rituximab may allow for improved outcomes without the use of doxorubicin. We assessed the efficacy of substituting etoposide for doxorubicin for patients with a contraindication to anthracyclines. Patients and Methods: Treatment guidelines in British Columbia (BC) recommend the substitution of etoposide for doxorubicin in standard dose R-CHOP for patients with DLBCL who have a contraindication to anthracyclines (R-CEOP). Etoposide is administered at a dose of 50 mg/m2 IV on day 1 and 100 mg/m2 PO on days 2 and 3 of each cycle. Patients with limited stage disease receive 3-4 cycles of chemotherapy with or without radiation therapy; patients with advanced stage disease receive 6 cycles of chemotherapy. We performed a retrospective population-based analysis using the BC Cancer Agency Lymphoid Cancer and pharmacy databases and included all patients with newly diagnosed DLBCL who were treated with curative intent with R-CEOP from December 2000 to March 2009. Patients who began treatment with R-CHOP but then switched to R-CEOP (due to intolerance or because a maximum threshold of anthracycline dosing was reached) were also included in the analysis if R-CEOP was administered for more than 50% of cycles delivered. Outcome of this population was compared with a 2:1 control group treated with R-CHOP in the same time period and matched for age, clinical stage and International Prognostic Index (IPI). End points were time to progression (TTP) and overall survival (OS). Results: We identified 81 patients treated with R-CEOP who met the stated inclusion criteria. Clinical characteristics were as follows: median age 73 y (range 34-93), 55 (68%) male, 15 (18%) limited stage and 66 (82%) advanced stage. Adverse prognostic factors according to the IPI were as follows: 85% age > 60 y, 58% stage III/IV, 31% PS > 1, 43% elevated LDH, and 12% > 1 extranodal site. IPI score: 19 (23%) low risk, 33 (41%) low-intermediate, 18 (22%) high-intermediate, and 11 (14%) high risk. Reasons for etoposide substitution were: 71 (88%) cardiac contraindication, 7 (9%) prior exposure to anthracyclines and 3 (4%) other co-morbidities. 72 (89%) patients received rituximab as part of the treatment, 25 (31%) received partial treatment with R-CHOP and then switched to R-CEOP and 56 (69%) received no anthracycline therapy. The control group included 162 randomly chosen patients matched for age, stage and IPI score and treated with R-CHOP. At a median follow-up of 28 months (range 3-86), 33/81 (41%) R-CEOP patients had died (23 with lymphoma, 3 treatment toxicity, 7 unrelated causes). The 5-year TTP was similar for patients treated with R-CEOP compared to patients in the R-CHOP control group, 57% versus 62%, respectively (p=0.21). (Fig. 1) The 5-y OS was lower for patients receiving R-CEOP compared with the R-CHOP control group (49% versus 64%, p=0.02), reflecting the underlying co-morbidities and frailty of this population. Interestingly, the 5-y TTP and 5-y OS rates were similar for patients in the R-CEOP cohort who had received partial treatment with an anthracycline and those who had received no anthracycline treatment (p=0.49 and p=0.77, respectively). Conclusions: A significant proportion of patients with DLBCL who are unable to receive anthracycline-based therapy can be cured with the etoposide-substituted regimen R-CEOP. R-CEOP is well tolerated even by patients with numerous co-morbidities. Moreover, the outcome of these patients does not appear to be significantly different compared to a similar population treated with standard R-CHOP. Disclosures: No relevant conflicts of interest to declare." @default.
• W2534379449 created "2016-10-28" @default.
• W2534379449 creator A5017873196 @default.
• W2534379449 creator A5021276970 @default.
• W2534379449 creator A5022658681 @default.
• W2534379449 creator A5023202154 @default.
• W2534379449 creator A5026641386 @default.
• W2534379449 creator A5031758990 @default.
• W2534379449 creator A5037428122 @default.
• W2534379449 creator A5059049347 @default.
• W2534379449 creator A5075117420 @default.
• W2534379449 date "2009-11-20" @default.
• W2534379449 modified "2023-10-16" @default.
• W2534379449 title "R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines." @default.
• W2534379449 doi "https://doi.org/10.1182/blood.v114.22.408.408" @default.
• W2534379449 hasPublicationYear "2009" @default.
• W2534379449 type Work @default.
• W2534379449 sameAs 2534379449 @default.
• W2534379449 citedByCount "30" @default.
• W2534379449 countsByYear W25343794492012 @default.
• W2534379449 countsByYear W25343794492013 @default.
• W2534379449 countsByYear W25343794492014 @default.
• W2534379449 countsByYear W25343794492015 @default.
• W2534379449 countsByYear W25343794492016 @default.
• W2534379449 countsByYear W25343794492017 @default.
• W2534379449 countsByYear W25343794492018 @default.
• W2534379449 countsByYear W25343794492019 @default.
• W2534379449 countsByYear W25343794492020 @default.
• W2534379449 countsByYear W25343794492021 @default.
• W2534379449 countsByYear W25343794492022 @default.
• W2534379449 crossrefType "journal-article" @default.
• W2534379449 hasAuthorship W2534379449A5017873196 @default.
• W2534379449 hasAuthorship W2534379449A5021276970 @default.
• W2534379449 hasAuthorship W2534379449A5022658681 @default.
• W2534379449 hasAuthorship W2534379449A5023202154 @default.
• W2534379449 hasAuthorship W2534379449A5026641386 @default.
• W2534379449 hasAuthorship W2534379449A5031758990 @default.
• W2534379449 hasAuthorship W2534379449A5037428122 @default.
• W2534379449 hasAuthorship W2534379449A5059049347 @default.
• W2534379449 hasAuthorship W2534379449A5075117420 @default.
• W2534379449 hasConcept C121608353 @default.
• W2534379449 hasConcept C126322002 @default.
• W2534379449 hasConcept C141071460 @default.
• W2534379449 hasConcept C142724271 @default.
• W2534379449 hasConcept C143998085 @default.
• W2534379449 hasConcept C204787440 @default.
• W2534379449 hasConcept C2776494729 @default.
• W2534379449 hasConcept C2776694085 @default.
• W2534379449 hasConcept C2776755627 @default.
• W2534379449 hasConcept C2776802502 @default.
• W2534379449 hasConcept C2778119113 @default.
• W2534379449 hasConcept C2779338263 @default.
• W2534379449 hasConcept C2779429289 @default.
• W2534379449 hasConcept C2780653079 @default.
• W2534379449 hasConcept C2780835546 @default.
• W2534379449 hasConcept C2781303535 @default.
• W2534379449 hasConcept C2908647359 @default.
• W2534379449 hasConcept C530470458 @default.
• W2534379449 hasConcept C71924100 @default.
• W2534379449 hasConcept C90924648 @default.
• W2534379449 hasConcept C99454951 @default.
• W2534379449 hasConceptScore W2534379449C121608353 @default.
• W2534379449 hasConceptScore W2534379449C126322002 @default.
• W2534379449 hasConceptScore W2534379449C141071460 @default.
• W2534379449 hasConceptScore W2534379449C142724271 @default.
• W2534379449 hasConceptScore W2534379449C143998085 @default.
• W2534379449 hasConceptScore W2534379449C204787440 @default.
• W2534379449 hasConceptScore W2534379449C2776494729 @default.
• W2534379449 hasConceptScore W2534379449C2776694085 @default.
• W2534379449 hasConceptScore W2534379449C2776755627 @default.
• W2534379449 hasConceptScore W2534379449C2776802502 @default.
• W2534379449 hasConceptScore W2534379449C2778119113 @default.
• W2534379449 hasConceptScore W2534379449C2779338263 @default.
• W2534379449 hasConceptScore W2534379449C2779429289 @default.
• W2534379449 hasConceptScore W2534379449C2780653079 @default.
• W2534379449 hasConceptScore W2534379449C2780835546 @default.
• W2534379449 hasConceptScore W2534379449C2781303535 @default.
• W2534379449 hasConceptScore W2534379449C2908647359 @default.
• W2534379449 hasConceptScore W2534379449C530470458 @default.
• W2534379449 hasConceptScore W2534379449C71924100 @default.
• W2534379449 hasConceptScore W2534379449C90924648 @default.
• W2534379449 hasConceptScore W2534379449C99454951 @default.
• W2534379449 hasIssue "22" @default.
• W2534379449 hasLocation W25343794491 @default.
• W2534379449 hasOpenAccess W2534379449 @default.
• W2534379449 hasPrimaryLocation W25343794491 @default.
• W2534379449 hasRelatedWork W1970186535 @default.
• W2534379449 hasRelatedWork W1984987955 @default.
• W2534379449 hasRelatedWork W2025962862 @default.
• W2534379449 hasRelatedWork W2034175082 @default.
• W2534379449 hasRelatedWork W2044128437 @default.
• W2534379449 hasRelatedWork W2062712570 @default.
• W2534379449 hasRelatedWork W2066069335 @default.
• W2534379449 hasRelatedWork W2358144868 @default.
• W2534379449 hasRelatedWork W2419391058 @default.
• W2534379449 hasRelatedWork W2909980364 @default.
• W2534379449 hasVolume "114" @default.
• W2534379449 isParatext "false" @default.

• next